Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, Wexner Medical Center at The Ohio State University, Columbus, OH, USA.
J Gastrointest Surg. 2017 Sep;21(9):1411-1419. doi: 10.1007/s11605-017-3479-x. Epub 2017 Jun 29.
Data evaluating the financial implications of volume-based referral are lacking. This study sought to compare in-hospital costs for pancreatic surgery by annual hospital volume.
Eleven thousand and eighty-one patients aged ≥18 years undergoing an elective pancreatic resection for cancer were identified using the Nationwide Inpatient Sample 2002-2011. Multivariable regression analysis was performed to compare length-of-stay (LOS), postoperative morbidity and mortality, failure-to-rescue (FTR), and inpatient costs by annual hospital volume group.
Patients undergoing surgery at high-volume hospitals (HVH) demonstrated 23% lower odds (odds ratio [OR] = 0.77, 95% confidence interval [95%CI] 0.63-0.95) of developing a postoperative complication, 59% lower odds of experiencing an LOS > 14 days (OR = 0.41, 95%CI 0.34-0.50), 51% lower odds of postoperative mortality (OR = 0.49, 95%CI 0.34-0.71), and 47% lower odds of FTR (OR = 0.53, 95%CI 0.37-0.76; all p<0.05). The overall mean in-hospital cost was $39,012 (SD = $15,214) with minimal differences observed across hospital volume groups. Rather, postoperative complications (no complication vs. complication $26,686 [SD = $5762] vs. $44,633 [SD = $11,637]) and FTR (rescue vs. FTR $42,413 [SD = $8481] vs. $69,546 [SD = $13,131]) were determinant of higher in-hospital costs. While this pattern was observed at all hospital volume groups, costs varied minimally between hospital volume groups after this stratification.
Annual hospital surgical volume was not associated with in-hospital costs among patients undergoing pancreatic surgery.
缺乏评估基于量的转诊所涉财务影响的数据。本研究旨在通过医院年手术量比较胰腺癌手术的住院费用。
利用 2002 年至 2011 年全国住院患者样本,确定了 11081 名年龄≥18 岁接受择期胰腺癌切除术的患者。采用多变量回归分析比较年手术量组间的住院时间(LOS)、术后发病率和死亡率、抢救失败(FTR)以及住院费用。
在高容量医院(HVH)接受手术的患者发生术后并发症的几率降低了 23%(优势比[OR]为 0.77,95%置信区间[95%CI]为 0.63-0.95),LOS>14 天的几率降低了 59%(OR 为 0.41,95%CI 为 0.34-0.50),术后死亡率降低了 51%(OR 为 0.49,95%CI 为 0.34-0.71),FTR 降低了 51%(OR 为 0.53,95%CI 为 0.37-0.76;均 P<0.05)。总住院费用平均为 39012 美元(标准差[SD]为 15214 美元),各医院量组间差异较小。相反,术后并发症(无并发症 vs. 并发症 26686 美元[SD 为 5762 美元] vs. 44633 美元[SD 为 11637 美元])和 FTR(抢救 vs. FTR 42413 美元[SD 为 8481 美元] vs. 69546 美元[SD 为 13131 美元])是导致更高住院费用的决定因素。尽管在所有医院量组中都观察到了这种模式,但在进行这种分层后,各医院量组之间的费用差异很小。
在接受胰腺癌手术的患者中,医院年手术量与住院费用无关。